Thermo Fisher Scientific Other accrued liabilities increased by 11.0% to $3.69B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 22.2%, from $3.02B to $3.69B. Over 5 years (FY 2020 to FY 2025), Other accrued liabilities shows an upward trend with a 7.5% CAGR.
Significant fluctuations may indicate changes in business model, such as shifts in deferred revenue recognition or changes in short-term regulatory obligations.
This category includes miscellaneous short-term obligations that are not classified under accounts payable or accrued li...
Commonly used as a catch-all for short-term liabilities; varies by industry and business model.
current_liabilities_other_liabilities_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.86B | $2.18B | $2.95B | $3.03B | $2.96B | $3.21B | $3.35B | $3.00B | $2.98B | $2.85B | $3.25B | $2.99B | $3.02B | $3.39B | $3.20B | $3.02B | $3.20B | $3.21B | $3.33B | $3.69B |
| QoQ Change | — | +16.9% | +35.6% | +2.8% | -2.5% | +8.4% | +4.6% | -10.7% | -0.7% | -4.3% | +14.0% | -8.0% | +1.1% | +12.4% | -5.7% | -5.5% | +5.9% | +0.3% | +3.7% | +11.0% |
| YoY Change | — | — | — | — | +58.9% | +47.4% | +13.7% | -1.2% | +0.6% | -11.2% | -3.2% | -0.3% | +1.5% | +19.1% | -1.4% | +1.2% | +6.0% | -5.4% | +4.1% | +22.2% |